Searching stem cell therapy Surprise? Start with your sore joint

What does the soreness usually mean?

An ache after walking that eases with rest often points to strain from use. Stiffness after sitting may ease once you move gently. Swelling can make it harder to bend a knee or lift an arm. Tell the doctor exactly which movement hurts and where you feel it.

Soreness while resting, a recent injury, or quick swelling needs closer attention. Say how the ache began and whether it’s changed. I’d mention an old injury or fall as well. The exam can check the joint, the muscles around it, and the bands joining muscle to bone.

What can make the joint feel better at home?

A short rest may calm a flare, though staying still too long can add stiffness. Gentle movement often feels better than a full day in bed. Warmth may relax a stiff joint, while ice may settle swelling. Use the one your doctor says fits your health.

A cane or brace can take some strain off the sore joint. You can also shorten a chore, so it doesn’t make the ache climb. Medicines take more care because other health problems matter. Don’t stop prescribed medicine or copy a friend’s routine.

When is an office visit worth it?

Consider an office visit once the ache regularly limits sleep, walking, work, or hobbies. Take old joint records and write down all your medicines. Ask what pressing and moving the joint showed. If a scan is suggested, ask which kind and what it’ll add.

One option is QC Kinetix’s regenerative treatments, office procedures in which a doctor or another licensed medical provider uses marrow taken from your pelvic bone, fat taken through a small skin opening, or platelets separated from your blood. Ask how that choice compares with exercise, medicine, or surgery. Find out what recovery could involve and what the written price covers. You’ll want answers tied to your exam, not a promise that every joint improves.

Sources

1. The 2018 AAOS/NIH consensus work group recommended that minimally manipulated mixed cell preparations be called CELL THERAPY rather than stem cell therapy, and that their untested and uncharacterised nature be clearly communicated to patients and the public, because stem cells have properties these preparations do not meet.

   Chu CR, et al. — Optimizing Clinical Use of Biologics in Orthopaedic Surgery: Consensus Recommendations From the 2018 AAOS/NIH U-13 Conference. J Am Acad Orthop Surg, 2019. DOI: 10.5435/JAAOS-D-18-00305.

2. The International Society for Cell & Gene Therapy position statement holds that the acronym MSC should mean mesenchymal STROMAL cells and should only be called stem cells where rigorous in vitro and in vivo evidence of stemness exists for that specific preparation.

   Viswanathan S, et al. — Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy, 2019. DOI: 10.1016/j.jcyt.2019.08.002.

3. The OARSI non-surgical management guideline evaluated 60 interventions with GRADE methodology and built its recommendations around core treatments - structured exercise, weight management and self-management education - for every patient with knee osteoarthritis, regardless of what else is added.

   Bannuru RR, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

4. In a 480-patient, four-arm, multicenter randomized phase 2/3 trial, none of three orthobiologic cell injections - autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, or allogeneic umbilical cord tissue-derived mesenchymal stromal cells - was superior to any other, or to a corticosteroid injection control, on pain at 12 months.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. Nat Med, 2023. DOI: 10.1038/s41591-023-02632-w.

5. FDA states in its consumer alert that the only FDA-approved stem cell products in the United States are blood-forming stem cells derived from umbilical cord blood, approved for disorders of the blood-forming system, and that NONE of these products - stem cells, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic fluid - has been approved for the treatment of any orthopedic condition, including osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain or shoulder pain.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. , 2020.

6. A retrospective comparison of 523 bone marrow aspiration procedures against 435 open iliac crest bone graft harvests found aspiration significantly reduced complications - relevant because marrow aspiration for a joint injection is a real procedure with a real, if low, complication rate.

   Hernigou P, et al. — Morbidity of graft harvesting versus bone marrow aspiration in cell regenerative therapy. Int Orthop, 2014. DOI: 10.1007/s00264-014-2318-x.